Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $275.23 -1.15%
Revenue Growth %: +5.5%
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.82, $0.10 better than the analyst estimate of $2.72. Revenue for the quarter came in at $22.45 billion versus the consensus estimate of $22.34 billion.
GUIDANCE:
Johnson & Johnson sees FY2024 EPS of $10.05, versus the consensus of $10.01.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
